Total Funding
76
46
Total FundingPost-IPO Equity raised
Growth Score
-9 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
33354
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Patrick Y. Lu: Founder, President and CEO
David Evans: Chief Scientific Officer and Co-Founder
About the Company
Sirnaomics is a clinical-stage biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology.
The RNAi technology is used to discover and develop novel therapeutics with a focus on oncology, anti-fibrotic therapeutics, and viral infection. Its proprietary Polypeptide Nano-Particle (PNP)
technology is used for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver.
Sirnaomics was founded by Patrick Y. Lu and David M. Evans in 2007 and is based in Gaithersburg, Maryland.
